Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence

  title={Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence},
  author={Karl Erik Andersson and Alan J. Wein},
  journal={Pharmacological Reviews},
  pages={581 - 631}
The lower urinary tract constitutes a functional unit controlled by a complex interplay between the central and peripheral nervous systems and local regulatory factors. In the adult, micturition is controlled by a spinobulbospinal reflex, which is under suprapontine control. Several central nervous system transmitters can modulate voiding, as well as, potentially, drugs affecting voiding; for example, noradrenaline, GABA, or dopamine receptors and mechanisms may be therapeutically useful… 

Figures and Tables from this paper

Therapeutic receptor targets for lower urinary tract dysfunction
In the overactive bladder (OAB) condition, therapeutic targets for facilitation of urine storage can be found at the levels of the urothelium, detrusor muscles, autonomic and afferent pathways, spinal cord, and brain, which can enhance urethral reflex activity during stress conditions and increase baseline Urethral pressure, respectively.
Drug Influence on Lower Urinary Tract
In vivo models were developed for the quantitative analysis of the effects of drugs on the function of the vesicourethral complex for urine bladder function and drug development.
Neural Mechanisms Underlying Lower Urinary Tract Dysfunction
This article summarizes anatomical, neurophysiological, and pharmacological studies in humans and animals to provide insights into the neural circuitry and neurotransmitter mechanisms controlling the
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology of voiding dysfunction and pharmacological therapy.
Theories of pharmacotherapy for voiding dysfunction are 1) increase detrusor contractility and 2) decrease urethral resistance.
The physiology and pharmacology of the lowerurinary tract
Several pharmaceutical approaches to manage OAB are possible which rely predominantly on manipulating mechanisms that generate detrusor contraction or reduce the magnitude of outflow obstruction, such as reducing sensations from the urinary tract or modulating central nervous system pathways.
Anatomy and physiology of the lower urinary tract.
Anatomy, Physiology and Pharmacology of the Lower Urinary Tract
The bladder and urethra constitute a functional unit controlled by a complex interplay between the central and peripheral nervous systems and local regulatory factors and various neurotransmitters have been implicated in this neural regulation.
Physiology and Pharmacology of the Bladder
The functions of the lower urinary tract (LUT) are to store and periodically release urine. These functions are dependent upon a complex interplay between the central and peripheral nervous systems
Neurotrophins in the Lower Urinary Tract: Becoming of Age
Available data indicates that NGF and BDNF might constitute future targets for designing new drugs for better treatment of bladder dysfunction, and those NTs may be key elements in the pathophysiology of bladder dysfunctions.


Nitric oxide in the lower urinary tract: physiological and pathological implications
Nitric oxide has increasingly gained recognition as an important cell mediator with a broad range of functions in the lower urinary tract, considered to be an important inhibitory NANC neurotransmitter as well as a modulator of the cellular immune response to invading microorganisms and tumour cells in theLower urinary tract of different animal species, including humans.
Pharmacology of the lower urinary tract.
This chapter will review recent advances in the understanding of the pathophysiology of voiding disorders and the targets for drug therapy.
Central nervous system control of the lower urinary tract: new pharmacological approaches to stress urinary incontinence in women.
Recent advances in mapping storage and micturition reflexes, and the association of serotonergic and noradrenergic systems with these reflexes are discussed, suggest increasing rhabdosphincter activity with duloxetine may offer a therapeutic benefit in women with stress urinary incontinence.
The pharmacological treatment of urinary incontinence
The present review of drugs in current use for the shown in most animal species, but seems to be of little treatment of urinary incontinence, agents specifically importance in normal human bladder muscle are included.
Advances in the pharmacological control of the bladder
To effectively control bladder activity, and to treat urinary incontinence caused by bladder overactivity, identification of suitable targets for pharmacological intervention is necessary and transmitters of afferent nerves and their receptors are possible targets for Pharmacological interventions.
Influence of central serotonergic mechanisms on lower urinary tract function.
Bladder activation: afferent mechanisms.
Current and future pharmacological treatment for overactive bladder.
Functional role of central muscarinic receptors for micturition in normal conscious rats.